{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T02:39:16Z","timestamp":1794623956273,"version":"4.9.1"},"reference-count":104,"publisher":"Ferrata Storti Foundation (Haematologica)","issue":"12","license":[{"start":{"date-parts":[[2025,3,20]],"date-time":"2025-03-20T00:00:00Z","timestamp":1742428800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["haematol"],"abstract":"<jats:p>Asparaginase (ASNase)-based chemotherapy regimens significantly improve survival outcomes in children, adolescents and young adults (AYA), and even adults with acute lymphoblastic leukemia\/lymphoma (ALL); however, the incidence and severity of ASNase-associated adverse events (AE) in adults may differ significantly from those reported in children. Strategies to mitigate, monitor for, and manage toxicities that allow adult ALL patients to receive full ASNase courses are needed. A representative 12-member panel of experts who treat AYA and adult ALL patients, incorporate ASNase into their treatment regimens, and conduct related research was assembled to consider opportunities to optimize the use of pediatric-inspired ALL regimens in these adult patients. Following 2 systematic biomedical literature searches from April 2009 through April 2024, a modified Delphi method was used to distill expert opinion into clinical statements that met a standardized definition of consensus. After 2 iterative Delphi method surveys, 23 statements met the standardized definition of consensus, whereas 19 statements did not. Five statements were merged to avoid redundancy. The clinical statements were grouped into 5 distinct categories: 1) hepatotoxicity; 2) hypersensitivity reactions; 3) thromboembolic and coagulopathy complications; 4) pancreatitis and metabolic complications; and 5) dosing. The intent of these statements is to provide health care providers with information that will help them mitigate, monitor for, and manage the most common and\/or unique ASNase-induced AE in adult ALL patients, allowing these patients to receive more or all the planned ASNase doses and thereby improve outcomes.<\/jats:p>","DOI":"10.3324\/haematol.2024.286744","type":"journal-article","created":{"date-parts":[[2025,3,20]],"date-time":"2025-03-20T04:20:38Z","timestamp":1742444438000},"page":"2913-2929","source":"Crossref","is-referenced-by-count":11,"title":["Recognition, prevention, and management of adverse events associated with asparaginase\/ pegaspargase treatment of acute lymphoblastic leukemia in adults: consensus of an expert panel"],"prefix":"10.3324","volume":"110","author":[{"given":"Emily","family":"Curran","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marlise R.","family":"Luskin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Houda","family":"Alachkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ibrahim","family":"Aldoss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick W.","family":"Burke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan D.","family":"Cassaday","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seth E.","family":"Karol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony J.","family":"Perissinotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecilie Utke","family":"Rank","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kjeld","family":"Schmiegelow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Webster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Douer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1856","published-online":{"date-parts":[[2025,3,20]]},"reference":[{"key":"82175","unstructured":"SEER. Cancer stat facts: leukemia \u2013 acute lymphocytic leukemia (ALL). 2024."},{"key":"82176","doi-asserted-by":"crossref","unstructured":"Bender C, Maese L, Carter-Febres M, Verma A. Clinical utility of pegaspargase in children, adolescents and young adult patients with acute lymphoblastic leukemia: a review. Blood Lymphat Cancer. 2021; 11:25-40.","DOI":"10.2147\/BLCTT.S245210"},{"key":"82177","doi-asserted-by":"crossref","unstructured":"Hunger SP, Mullighan CG. Acute lymphoblastic leukemia in children. N Engl J Med. 2015; 373(16):1541-1552.","DOI":"10.1056\/NEJMra1400972"},{"key":"82178","doi-asserted-by":"crossref","unstructured":"Nunes JCF, Crist\u00f3v\u00e3o RO, Freire MG. Recent strategies and applications for L-asparaginase confinement. Molecules. 2020; 25(24):5827.","DOI":"10.3390\/molecules25245827"},{"key":"82179","unstructured":"Avramis VI, Tiwari PN. Asparaginase (native ASNase or pegylated ASNase) in the treatment of acute lymphoblastic leukemia. Int J Nanomedicine. 2006; 1(3):241-254."},{"key":"82180","doi-asserted-by":"crossref","unstructured":"Aldoss I, Pourhassan H, Douer D. SOHO state of the art updates and next questions | asparaginase - understanding and overcoming toxicities in adults with ALL. Clin Lymphoma Myeloma Leuk. 2022; 22(11):787-794.","DOI":"10.1016\/j.clml.2022.08.009"},{"key":"82181","doi-asserted-by":"crossref","unstructured":"Juluri KR, Siu C, Cassaday RD. Asparaginase in the treatment of acute lymphoblastic leukemia in adults: current evidence and place in therapy. Blood Lymphat Cancer. 2022; 12:55-79.","DOI":"10.2147\/BLCTT.S342052"},{"key":"82182","doi-asserted-by":"crossref","unstructured":"Miller KD, Fidler-Benaoudia M, Keegan TH, Hipp HS, Jemal A, Siegel RL. Cancer statistics for adolescents and young adults, 2020. CA Cancer J Clin. 2020; 70(6):443-459.","DOI":"10.3322\/caac.21637"},{"key":"82183","doi-asserted-by":"crossref","unstructured":"Geyer MB, Hsu M, Devlin SM, Tallman MS, Douer D, Park JH. Overall survival among older US adults with ALL remains low despite modest improvement since 1980: SEER analysis. Blood. 2017; 129(13):1878-1881.","DOI":"10.1182\/blood-2016-11-749507"},{"key":"82184","doi-asserted-by":"crossref","unstructured":"Hallb\u00f6\u00f6k H, Gustafsson G, Smedmyr B, S\u00f6derh\u00e4ll S, Heyman M, for the Swedish Adult Acute Lymphocytic Leukemia Group and the Swedish Childhood Leukemia Group. Treatment outcome in young adults and children &gt;10 years of age with acute lymphoblastic leukemia in Sweden: a comparison between a pediatric protocol and an adult protocol. Cancer. 2006; 107(7):1551-1561.","DOI":"10.1002\/cncr.22189"},{"key":"82185","doi-asserted-by":"crossref","unstructured":"Roberts KG. Genetics and prognosis of ALL in children vs adults. Hematology Am Soc Hematol Educ Program. 2018; 2018(1):137-145.","DOI":"10.1182\/asheducation-2018.1.137"},{"key":"82186","doi-asserted-by":"crossref","unstructured":"Thomas X, Le QH. Prognostic factors in adult acute lymphoblastic leukemia. Hematology. 2003; 8(4):233-242.","DOI":"10.1080\/1024533031000153621"},{"key":"82187","doi-asserted-by":"crossref","unstructured":"Huguet F, Chevret S, Leguay T. Intensified therapy of acute lymphoblastic leukemia in adults: report of the randomized GRAALL-2005 clinical trial. J Clin Oncol. 2018; 36(24):2514-2523.","DOI":"10.1200\/JCO.2017.76.8192"},{"key":"82188","doi-asserted-by":"crossref","unstructured":"Wetzler M, Sanford BL, Kurtzberg J. Effective asparagine depletion with pegylated asparaginase results in improved outcomes in adult acute lymphoblastic leukemia: Cancer and Leukemia Group B Study 9511. Blood. 2007; 109(10):4164-4167.","DOI":"10.1182\/blood-2006-09-045351"},{"key":"82189","doi-asserted-by":"crossref","unstructured":"Huguet F, Leguay T, Raffoux E. Pediatric-inspired therapy in adults with Philadelphia chromosome\u2013negative acute lymphoblastic leukemia: the GRAALL-2003 study. J Clin Oncol. 2009; 27(6):911-918.","DOI":"10.1200\/JCO.2008.18.6916"},{"key":"82190","doi-asserted-by":"crossref","unstructured":"Stock W, Luger SM, Advani AS. A pediatric regimen for older adolescents and young adults with acute lymphoblastic leukemia: results of CALGB 10403. Blood. 2019; 133(14):1548-1559.","DOI":"10.1182\/blood-2018-10-881961"},{"key":"82191","doi-asserted-by":"crossref","unstructured":"Toft N, Birgens H, Abrahamsson J. Results of NOPHO ALL2008 treatment for patients aged 1-45 years with acute lymphoblastic leukemia. Leukemia. 2018; 32(3):606-615.","DOI":"10.1038\/leu.2017.265"},{"key":"82192","doi-asserted-by":"crossref","unstructured":"Hijiya N, van der Sluis IM. Asparaginase-associated toxicity in children with acute lymphoblastic leukemia. Leuk Lymphoma. 2016; 57(4):748-757.","DOI":"10.3109\/10428194.2015.1101098"},{"key":"82193","doi-asserted-by":"crossref","unstructured":"Douer D, G\u00f6kbuget N, Stock W, Boissel N. Optimizing use of L-asparaginase\u2013based treatment of adults with acute lymphoblastic leukemia. Blood Rev. 2022; 53:100908.","DOI":"10.1016\/j.blre.2021.100908"},{"key":"82194","doi-asserted-by":"crossref","unstructured":"Aldoss I, Yin J, Wall A. The impact of early PEG-asparaginase discontinuation in young adults with ALL: a post hoc analysis of the CALGB 10403 study. Blood Adv. 2023; 7(2):196-204.","DOI":"10.1182\/bloodadvances.2022007791"},{"key":"82195","doi-asserted-by":"crossref","unstructured":"Gupta S, Wang C, Raetz EA. Impact of asparaginase discontinuation on outcome in childhood acute lymphoblastic leukemia: a report from the Children\u2019s Oncology Group. J Clin Oncol. 2020; 38(17):1897-1905.","DOI":"10.1200\/JCO.19.03024"},{"key":"82196","doi-asserted-by":"crossref","unstructured":"Dinndorf PA, Gootenberg J, Cohen MH, Keegan P, Pazdur R. FDA drug approval summary: pegaspargase (Oncaspar) for the first-line treatment of children with acute lymphoblastic leukemia (ALL). Oncologist. 2007; 12(8):991-998.","DOI":"10.1634\/theoncologist.12-8-991"},{"key":"82197","doi-asserted-by":"crossref","unstructured":"Graham ML. Pegaspargase: a review of clinical studies. Adv Drug Deliv Rev. 2003; 55(10):1293-1302.","DOI":"10.1016\/S0169-409X(03)00110-8"},{"key":"82198","unstructured":"Servier Pharmaceuticals LLC. ONCASPAR\u2192 (pegaspargase). Prescribing Information. 2024."},{"key":"82199","doi-asserted-by":"crossref","unstructured":"Stock W, Douer D, DeAngelo DJ. Prevention and management of asparaginase \/ pegasparaginase-associated toxicities in adults and older adolescents: recommendations of an expert panel. Leuk Lymphoma. 2011; 52(12):2237-2253.","DOI":"10.3109\/10428194.2011.596963"},{"key":"82200","doi-asserted-by":"crossref","unstructured":"Burke PW, Aldoss I, Lunning MA. Pegaspargase-related high-grade hepatotoxicity in a pediatric-inspired adult acute lymphoblastic leukemia regimen does not predict recurrent hepatotoxicity with subsequent doses. Leuk Res. 2018; 66:49-56.","DOI":"10.1016\/j.leukres.2017.12.013"},{"key":"82201","doi-asserted-by":"crossref","unstructured":"Douer D, Aldoss I, Lunning MA. Pharmacokinetics-based integration of multiple doses of intravenous pegaspargase in a pediatric regimen for adults with newly diagnosed acute lymphoblastic leukemia. J Clin Oncol. 2014; 32(9):905-911.","DOI":"10.1200\/JCO.2013.50.2708"},{"key":"82202","doi-asserted-by":"crossref","unstructured":"Patel B, Kirkwood AA, Dey A. Pegylated-asparaginase during induction therapy for adult acute lymphoblastic leukaemia: toxicity data from the UKALL14 trial. Leukemia. 2017; 31(1):58-64.","DOI":"10.1038\/leu.2016.219"},{"key":"82203","doi-asserted-by":"crossref","unstructured":"Aldoss I, Douer D, Behrendt CE. Toxicity profile of repeated doses of PEG-asparaginase incorporated into a pediatric-type regimen for adult acute lymphoblastic leukemia. Eur J Haematol. 2016; 96(4):375-380.","DOI":"10.1111\/ejh.12600"},{"key":"82204","doi-asserted-by":"crossref","unstructured":"Burke PW, Hoelzer D, Park JH, Schmiegelow K, Douer D. Managing toxicities with asparaginase-based therapies in adult ALL: summary of an ESMO Open-Cancer Horizons roundtable discussion. ESMO Open. 2020; 5(5):e000858.","DOI":"10.1136\/esmoopen-2020-000858"},{"key":"82205","doi-asserted-by":"crossref","unstructured":"Trang E, Ngo D, Chen J, Aldoss I, Salhotra A, Pullarkat V. Levocarnitine for pegasparaginase-induced hepatotoxicity in acute lymphoblastic leukemia. Leuk Lymphoma. 2020; 61(13):3161-3164.","DOI":"10.1080\/10428194.2020.1805108"},{"key":"82206","doi-asserted-by":"crossref","unstructured":"Advani AS, Sanford B, Luger S. Frontline-treatment of acute lymphoblastic leukemia (ALL) in older adolescents and young adults (AYA) using a pediatric regimen is feasible: toxicity results of the prospective US intergroup trial C10403 (Alliance). Blood. 2013; 122(21):3903.","DOI":"10.1182\/blood.V122.21.3903.3903"},{"key":"82207","doi-asserted-by":"crossref","unstructured":"Goekbuget N, Baumann A, Beck J. Peg-asparaginase intensification in adult acute lymphoblastic leukemia (ALL): significant improvement of outcome with moderate increase of liver toxicity in the German Multicenter Study Group for Adult ALL (GMALL) Study 07\/2003. Blood. 2010; 116(21):494.","DOI":"10.1182\/blood.V116.21.494.494"},{"key":"82208","doi-asserted-by":"crossref","unstructured":"Denton CC, Rawlins YA, Oberley MJ, Bhojwani D, Orgel E. Predictors of hepatotoxicity and pancreatitis in children and adolescents with acute lymphoblastic leukemia treated according to contemporary regimens. Pediatr Blood Cancer. 2018; 65(3):e26891.","DOI":"10.1002\/pbc.26891"},{"key":"82209","doi-asserted-by":"crossref","unstructured":"Geyer MB, Ritchie EK, Rao AV. Pediatric-inspired chemotherapy incorporating pegaspargase is safe and results in high rates of minimal residual disease negativity in adults up to age 60 with Philadelphia chromosome-negative acute lymphoblastic leukemia. Haematologica. 2021; 106(8):2086-2094.","DOI":"10.3324\/haematol.2020.251686"},{"key":"82210","doi-asserted-by":"crossref","unstructured":"Rausch CR, Marini BL, Benitez LL. PEGging down risk factors for peg-asparaginase hepatotoxicity in patients with acute lymphoblastic leukemia. Leuk Lymphoma. 2018; 59(3):617-624.","DOI":"10.1080\/10428194.2017.1349902"},{"key":"82211","doi-asserted-by":"crossref","unstructured":"DeAngelo DJ, Stevenson K, Neuberg DS. A multicenter phase II study using a dose intensified pegylated-asparaginase pediatric regimen in adults with untreated acute lymphoblastic leukemia: a DFCI ALL Consortium Trial. Blood. 2015; 126(23):80.","DOI":"10.1182\/blood.V126.23.80.80"},{"key":"82212","doi-asserted-by":"crossref","unstructured":"Derman BA, Streck M, Wynne J. Efficacy and toxicity of reduced vs. standard dose pegylated asparaginase in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia. Leuk Lymphoma. 2020; 61(3):614-622.","DOI":"10.1080\/10428194.2019.1680839"},{"key":"82213","doi-asserted-by":"crossref","unstructured":"Douer D, Yampolsky H, Cohen LJ. Pharmacodynamics and safety of intravenous pegaspargase during remission induction in adults aged 55 years or younger with newly diagnosed acute lymphoblastic leukemia. Blood. 2007; 109(7):2744-2750.","DOI":"10.1182\/blood-2006-07-035006"},{"key":"82214","doi-asserted-by":"crossref","unstructured":"Tinajero J, Xu S, Ngo D. Delaying pegaspargase during induction in adults with acute lymphoblastic leukaemia is associated with lower risk of high-grade hepatotoxicity without adversely impacting outcomes. Br J Haematol. 2025; 206(3):868-875.","DOI":"10.1111\/bjh.19880"},{"key":"82215","doi-asserted-by":"crossref","unstructured":"Roesmann A, Afify M, Panse J, Eisert A, Steitz J, Tolba RH. L-carnitine ameliorates L-asparaginase-induced acute liver toxicity in steatotic rat livers. Chemotherapy. 2013; 59(3):167-175.","DOI":"10.1159\/000353402"},{"key":"82216","doi-asserted-by":"crossref","unstructured":"Liu Y, Janke LJ, Li L, Relling MV. L-carnitine does not ameliorate asparaginase-associated hepatotoxicity in a C57BL6 mouse model. Leuk Lymphoma. 2019; 60(8):2088-2090.","DOI":"10.1080\/10428194.2019.1571198"},{"key":"82217","doi-asserted-by":"crossref","unstructured":"Blackman A, Boutin A, Shimanovsky A, Baker WJ, Forcello N. Levocarnitine and vitamin B complex for the treatment of pegaspargase-induced hepatotoxicity: a case report and review of the literature. J Oncol Pharm Pract. 2018; 24(5):393-397.","DOI":"10.1177\/1078155217710714"},{"key":"82218","doi-asserted-by":"crossref","unstructured":"Wieduwilt MJ, Goodman A, Jonas BA. L-carnitine for pegylated-L-asparaginase induced hepatotoxicity. J Clin Oncol. 2017; 35(15 Suppl):e21626.","DOI":"10.1200\/JCO.2017.35.15_suppl.e21626"},{"key":"82219","doi-asserted-by":"crossref","unstructured":"Schulte R, Hinson A, Huynh V. Levocarnitine for pegaspargase-induced hepatotoxicity in older children and young adults with acute lymphoblastic leukemia. Cancer Med. 2021; 10(21):7551-7560.","DOI":"10.1002\/cam4.4281"},{"key":"82220","unstructured":"Children\u2019s Oncology Group. A randomized trial of levocarnitine prophylaxis to prevent asparaginase-associated hepatotoxicity in adolescents and young adults receiving acute lymphoblastic leukemia therapy (NCT05602194), Updated May 16. 2024."},{"key":"82221","doi-asserted-by":"crossref","unstructured":"Aldoss I, Douer D. How I treat the toxicities of pegasparaginase in adults with acute lymphoblastic leukemia. Blood. 2020; 135(13):987-995.","DOI":"10.1182\/blood.2019002477"},{"key":"82222","doi-asserted-by":"crossref","unstructured":"Raetz EA, Salzer WL. Tolerability and efficacy of L-asparaginase therapy in pediatric patients with acute lymphoblastic leukemia. J Pediatr Hematol Oncol. 2010; 32(7):554-563.","DOI":"10.1097\/MPH.0b013e3181e6f003"},{"key":"82223","doi-asserted-by":"crossref","unstructured":"van der Sluis IM, Vrooman LM, Pieters R. Consensus expert recommendations for identification and management of asparaginase hypersensitivity and silent inactivation. Haematologica. 2016; 101(3):279-285.","DOI":"10.3324\/haematol.2015.137380"},{"key":"82224","doi-asserted-by":"crossref","unstructured":"Tong WH, Pieters R, Kaspers GJL. A prospective study on drug monitoring of PEGasparaginase and Erwinia asparaginase and asparaginase antibodies in pediatric acute lymphoblastic leukemia. Blood. 2014; 123(13):2026-2033.","DOI":"10.1182\/blood-2013-10-534347"},{"key":"82225","doi-asserted-by":"crossref","unstructured":"Vrooman LM, Supko JG, Neuberg DS. Erwinia asparaginase after allergy to E. coli asparaginase in children with acute lymphoblastic leukemia. Pediatr Blood Cancer. 2010; 54(2):199-205.","DOI":"10.1002\/pbc.22225"},{"key":"82226","unstructured":"Bianchi A, Bottau P, Calamelli E. Hypersensitivity to polyethylene glycol in adults and children: an emerging challenge. Acta Biomed. 2021; 92(S7):e2021519."},{"key":"82227","doi-asserted-by":"crossref","unstructured":"Khalil A, W\u00fcrthwein G, Golitsch J. Pre-existing antibodies against polyethylene glycol reduce asparaginase activities on first administration of pegylated E. coli asparaginase in children with acute lymphocytic leukemia. Haematologica. 2022; 107(1):49-57.","DOI":"10.3324\/haematol.2020.258525"},{"key":"82228","unstructured":"National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. 2017."},{"key":"82229","doi-asserted-by":"crossref","unstructured":"Vogel WH. Infusion reactions: diagnosis, assessment, and management. Clin J Oncol Nurs. 2010; 14(2):E10-E21.","DOI":"10.1188\/10.CJON.E10-E21"},{"key":"82230","doi-asserted-by":"crossref","unstructured":"Burke MJ, Rheingold SR. Differentiating hypersensitivity versus infusion-related reactions in pediatric patients receiving intravenous asparaginase therapy for acute lymphoblastic leukemia. Leuk Lymphoma. 2017; 58(3):540-551.","DOI":"10.1080\/10428194.2016.1213826"},{"key":"82231","doi-asserted-by":"crossref","unstructured":"Zalewska-Szewczyk B, Andrzejewski W, M\u0142ynarski W, J\u0119drychowska-Da\u0144ska K, Witas H, Bodalski J. The anti-asparagines antibodies correlate with L-asparagines activity and may affect clinical outcome of childhood acute lymphoblastic leukemia. Leuk Lymphoma. 2007; 48(5):931-936.","DOI":"10.1080\/10428190701292049"},{"key":"82232","doi-asserted-by":"crossref","unstructured":"Gottschalk H\u00f8jfeldt S, Grell K, Abrahamsson J. Relapse risk following truncation of pegylated asparaginase in childhood acute lymphoblastic leukemia. Blood. 2021; 137(17):2373-2382.","DOI":"10.1182\/blood.2020006583"},{"key":"82233","doi-asserted-by":"crossref","unstructured":"Vrooman LM, Stevenson KE, Supko JG. Postinduction dexamethasone and individualized dosing of Escherichia coli L-asparaginase each improve outcome of children and adolescents with newly diagnosed acute lymphoblastic leukemia: results from a randomized study-Dana-Farber Cancer Institute ALL Consortium Protocol 00-01. J Clin Oncol. 2013; 31(9):1202-1210.","DOI":"10.1200\/JCO.2012.43.2070"},{"key":"82234","doi-asserted-by":"crossref","unstructured":"Heitink-Poll\u00e9 KMJ, Prinsen BHCMT, De Koning TJ, van Hasselt PM, Bierings MB. High incidence of symptomatic hyperammonemia in children with acute lymphoblastic leukemia receiving pegylated asparaginase. Springer Berlin Heidelberg;. 2013; 7:103-108.","DOI":"10.1007\/8904_2012_156"},{"key":"82235","doi-asserted-by":"crossref","unstructured":"Lanvers-Kaminsky C, Westhoff PS, D\u2019Incalci M, Zucchetti M, Boos J. Immediate cooling does not prevent the ex vivo hydrolysis of L-asparagine by asparaginase. Ther Drug Monit. 2014; 36(4):549-552.","DOI":"10.1097\/FTD.0000000000000030"},{"key":"82236","doi-asserted-by":"crossref","unstructured":"Bleyer A, Asselin BL, Koontz SE, Hunger SP. Clinical application of asparaginase activity levels following treatment with pegaspargase. Pediatr Blood Cancer. 2015; 62(6):1102-1105.","DOI":"10.1002\/pbc.25299"},{"key":"82237","doi-asserted-by":"crossref","unstructured":"Levi-Schaffer F, Eliashar R. Mast cell stabilizing properties of antihistamines. J Invest Dermatol. 2009; 129(11):2549-2551.","DOI":"10.1038\/jid.2009.256"},{"key":"82238","doi-asserted-by":"crossref","unstructured":"Baruchel A, Brown P, Rizzari C. Increasing completion of asparaginase treatment in childhood acute lymphoblastic leukaemia (ALL): summary of an expert panel discussion. ESMO Open. 2020; 5(5):e000977.","DOI":"10.1136\/esmoopen-2020-000977"},{"key":"82239","doi-asserted-by":"crossref","unstructured":"Losasso M, Bostrom B, Messinger Y. Retrospective cohort study monitoring PEG-asparaginase activity in acute lymphoblastic leukemia patients with and without premedication [version 2; peer review: 1 approved, 2 approved with reservations]. F1000Res. 2020; 8:1007.","DOI":"10.12688\/f1000research.19298.2"},{"key":"82240","doi-asserted-by":"crossref","unstructured":"Menig S, Dinh A, Angus J. Lack of benefit from premedication for pegylated asparaginase during pediatric acute lymphoblastic leukemia\/lymphoma therapy: a side-by-side comparison. Pediatr Blood Cancer. 2024; 71(1):e30716.","DOI":"10.1002\/pbc.30716"},{"key":"82241","doi-asserted-by":"crossref","unstructured":"Eden D, Hipkins R, Bradbury CA. Cerebral thrombotic complications related to L-asparaginase treatment for acute lymphoblastic leukemia: retrospective review of 10 cases. Clin Appl Thromb Hemost. 2016; 22(6):589-593.","DOI":"10.1177\/1076029615572464"},{"key":"82242","doi-asserted-by":"crossref","unstructured":"Rank CU, Toft N, Tuckuviene R. Thromboembolism in acute lymphoblastic leukemia: results of NOPHO ALL2008 protocol treatment in patients aged 1 to 45 years [published correction appears in Blood. Blood. 2020; 135(10):780-2484.","DOI":"10.1182\/blood.2020005128"},{"key":"82243","doi-asserted-by":"crossref","unstructured":"De Stefano V, Za T, Ciminello A, Betti S, Rossi E. Haemostatic alterations induced by treatment with asparaginases and clinical consequences. Thromb Haemost. 2015; 113(02):247-261.","DOI":"10.1160\/TH14-04-0372"},{"key":"82244","doi-asserted-by":"crossref","unstructured":"Grace RF, Dahlberg SE, Neuberg D. The frequency and management of asparaginase-related thrombosis in paediatric and adult patients with acute lymphoblastic leukaemia treated on Dana-Farber Cancer Institute consortium protocols. Br J Haematol. 2011; 152(4):452-459.","DOI":"10.1111\/j.1365-2141.2010.08524.x"},{"key":"82245","doi-asserted-by":"crossref","unstructured":"Goyal G, Bhatt VR. L-asparaginase and venous thromboembolism in acute lymphocytic leukemia. Future Oncol. 2015; 11(17):2459-2470.","DOI":"10.2217\/fon.15.114"},{"key":"82246","doi-asserted-by":"crossref","unstructured":"Orvain C, Balsat M, Tavernier E. Thromboembolism prophylaxis in adult patients with acute lymphoblastic leukemia treated in the GRAALL-2005 study. Blood. 2020; 136(3):328-338.","DOI":"10.1182\/blood.2020004919"},{"key":"82247","doi-asserted-by":"crossref","unstructured":"Rank CU, Lynggaard LS, Als-Nielsen B. Prophylaxis of thromboembolism during therapy with asparaginase in adults with acute lymphoblastic leukaemia. Cochrane Database Syst Rev. 2020; 10(10):CD013399.","DOI":"10.1002\/14651858.CD013399.pub2"},{"key":"82248","doi-asserted-by":"crossref","unstructured":"Grace RF, DeAngelo DJ, Stevenson KE. The use of prophylactic anticoagulation during induction and consolidation chemotherapy in adults with acute lymphoblastic leukemia. J Thromb Thrombolysis. 2018; 45(2):306-314.","DOI":"10.1007\/s11239-017-1597-7"},{"key":"82249","doi-asserted-by":"crossref","unstructured":"Greiner J, Schrappe M, Claviez A. THROMBOTECT \u2013 a randomized study comparing low molecular weight heparin, antithrombin and unfractionated heparin for thromboprophylaxis during induction therapy of acute lymphoblastic leukemia in children and adolescents. Haematologica. 2019; 104(4):756-765.","DOI":"10.3324\/haematol.2018.194175"},{"key":"82250","doi-asserted-by":"crossref","unstructured":"O\u2019Brien SH, Rodriguez V, Lew G. Apixaban versus no anticoagulation for the prevention of venous thromboembolism in children with newly diagnosed acute lymphoblastic leukaemia or lymphoma (PREVAPIX-ALL): a phase 3, open-label, randomised, controlled trial. Lancet Haematol. 2024; 11(1):e27-e37.","DOI":"10.1016\/S2352-3026(23)00314-9"},{"key":"82251","doi-asserted-by":"crossref","unstructured":"Chen J, Ngo D, Aldoss I, Shayani S, Tsai NC, Pullarkat V. Antithrombin supplementation did not impact the incidence of pegylated asparaginase-induced venous thromboembolism in adults with acute lymphoblastic leukemia. Leuk Lymphoma. 2019; 60(5):1187-1192.","DOI":"10.1080\/10428194.2018.1519811"},{"key":"82252","doi-asserted-by":"crossref","unstructured":"Anderson D, Gangaraju R, Sedhom W. Derivation and external validation of a venous thromboembolism risk prediction model in patients with acute lymphoblastic leukemia receiving asparaginase therapy. Blood. 2024; 144(Suppl 1):1250.","DOI":"10.1182\/blood-2024-201997"},{"key":"82253","doi-asserted-by":"crossref","unstructured":"Skipper MT, Rank CU, Jarvis KB. Cerebral sinovenous thrombosis and asparaginase re-exposure in patients aged 1-45 years with acute lymphoblastic leukaemia: a NOPHO ALL2008 study. EJHaem. 2022; 3(3):754-763.","DOI":"10.1002\/jha2.484"},{"key":"82254","doi-asserted-by":"crossref","unstructured":"Lussana F, Minetto P, Ferrara F, Chiaretti S, Specchia G, Bassan R. National Italian Delphi panel consensus: which measures are indicated to minimize pegylated-asparaginase associated toxicity during treatment of adult acute lymphoblastic leukemia?. BMC Cancer. 2020; 20(1):956.","DOI":"10.1186\/s12885-020-07461-5"},{"key":"82255","doi-asserted-by":"crossref","unstructured":"Rank CU, Wolthers BO, Grell K. Asparaginase-associated pancreatitis in acute lymphoblastic leukemia: results from the NOPHO ALL2008 treatment of patients 1-45 years of age. J Clin Oncol. 2020; 38(2):145-154.","DOI":"10.1200\/JCO.19.02208"},{"key":"82256","doi-asserted-by":"crossref","unstructured":"Wolthers BO, Frandsen TL, Baruchel A. Asparaginase-associated pancreatitis in childhood acute lymphoblastic leukaemia: an observational Ponte di Legno Toxicity Working Group study. Lancet Oncol. 2017; 18(9):1238-1248.","DOI":"10.1016\/S1470-2045(17)30424-2"},{"key":"82257","doi-asserted-by":"crossref","unstructured":"Wolthers BO, Frandsen TL, Abrahamsson J. Asparaginase-associated pancreatitis: a study on phenotype and genotype in the NOPHO ALL2008 protocol. Leukemia. 2017; 31(2):325-332.","DOI":"10.1038\/leu.2016.203"},{"key":"82258","doi-asserted-by":"crossref","unstructured":"Gibson A, Hernandez C, Tejada FNH, Kawedia J, Rytting M, Cuglievan B. Asparaginase-associated pancreatitis in pediatric patients with acute lymphoblastic leukemia: current perspectives. Pediatr Drugs. 2021; 23(5):457-463.","DOI":"10.1007\/s40272-021-00463-1"},{"key":"82259","doi-asserted-by":"crossref","unstructured":"Oparaji JA, Rose F, Okafor D. Risk factors for asparaginase-associated pancreatitis: a systematic review. J Clin Gastroenterol. 2017; 51(10):907-913.","DOI":"10.1097\/MCG.0000000000000827"},{"key":"82260","doi-asserted-by":"crossref","unstructured":"Liu C, Yang W, Devidas M. Clinical and genetic risk factors for acute pancreatitis in patients with acute lymphoblastic leukemia. J Clin Oncol. 2016; 34(18):2133-2140.","DOI":"10.1200\/JCO.2015.64.5812"},{"key":"82261","doi-asserted-by":"crossref","unstructured":"Lynggaard LS, Rank CU, Hansen SN. Asparaginase enzyme activity levels and toxicity in childhood acute lymphoblastic leukemia: a NOPHO ALL2008 study. Blood Adv. 2022; 6(1):138-147.","DOI":"10.1182\/bloodadvances.2021005631"},{"key":"82262","doi-asserted-by":"crossref","unstructured":"Wolthers BO, Frandsen TL, Patel CJ. Trypsin-encoding PRSS1-PRSS2 variations influence the risk of asparaginase-associated pancreatitis in children with acute lymphoblastic leukemia: a Ponte di Legno toxicity working group report. Haematologica. 2019; 104(3):556-563.","DOI":"10.3324\/haematol.2018.199356"},{"key":"82263","doi-asserted-by":"crossref","unstructured":"Christ TN, Stock W, Knoebel RW. Incidence of asparaginase-related hepatotoxicity, pancreatitis, and thrombotic events in adults with acute lymphoblastic leukemia treated with a pediatric-inspired regimen. J Oncol Pharm Pract. 2018; 24(4):299-308.","DOI":"10.1177\/1078155217701291"},{"key":"82264","doi-asserted-by":"crossref","unstructured":"Mogensen SS, Harila-Saari A, M\u00e4kitie O. Comparing osteonecrosis clinical phenotype, timing, and risk factors in children and young adults treated for acute lymphoblastic leukemia. Pediatr Blood Cancer. 2018; 65(10):e27300.","DOI":"10.1002\/pbc.27300"},{"key":"82265","doi-asserted-by":"crossref","unstructured":"Valtis YK, Stevenson KE, Place AE. Orthopedic toxicities among adolescents and young adults treated in DFCI ALL Consortium Trials. Blood Adv. 2022; 6(1):72-81.","DOI":"10.1182\/bloodadvances.2021005278"},{"key":"82266","doi-asserted-by":"crossref","unstructured":"Larsen EC, Devidas M, Chen S. Dexamethasone and high-dose methotrexate improve outcome for children and young adults with high-risk B-acute lymphoblastic leukemia: a report from Children\u2019s Oncology Group study AALL0232. J Clin Oncol. 2016; 34(20):2380-2388.","DOI":"10.1200\/JCO.2015.62.4544"},{"key":"82267","doi-asserted-by":"crossref","unstructured":"Bhojwani D, Darbandi R, Pei D. Severe hypertriglyceridaemia during therapy for childhood acute lymphoblastic leukaemia. Eur J Cancer. 2014; 50(15):2685-2694.","DOI":"10.1016\/j.ejca.2014.06.023"},{"key":"82268","doi-asserted-by":"crossref","unstructured":"Finch ER, Smith CA, Yang W. Asparaginase formulation impacts hypertriglyceridemia during therapy for acute lymphoblastic leukemia. Pediatr Blood Cancer. 2020; 67(1):e28040.","DOI":"10.1002\/pbc.28040"},{"key":"82269","doi-asserted-by":"crossref","unstructured":"Laumann RD, Pedersen LL, Andr\u00e9s-Jensen L. Hyperlipidemia in children and adolescents with acute lymphoblastic leukemia: a systematic review and meta-analysis. Pediatr Blood Cancer. 2023; 70(12):e30683.","DOI":"10.1002\/pbc.30683"},{"key":"82270","doi-asserted-by":"crossref","unstructured":"Lanvers-Kaminsky C, Niemann A, Eveslage M. Asparaginase activities during intensified treatment with pegylated E. coli asparaginase in adults with newly-diagnosed acute lymphoblastic leukemia. Leuk Lymphoma. 2020; 61(1):138-145.","DOI":"10.1080\/10428194.2019.1658099"},{"key":"82271","doi-asserted-by":"crossref","unstructured":"Baek G, Kim M, Lee M. Retrospective review of the toxicities and change in dosing patterns for pegaspargase in patients with acute lymphoblastic leukemia\/lymphoma and T-cell lymphoma. J Oncol Pharm Pract. 2025; 31(4):534-544.","DOI":"10.1177\/10781552241246104"},{"key":"82272","doi-asserted-by":"crossref","unstructured":"Lebovic R, Pearce N, Lacey L, Xenakis J, Faircloth CB, Thompson P. Adverse effects of pegaspargase in pediatric patients receiving doses greater than 3,750 IU. Pediatr Blood Cancer. 2017; 64(10):e26555.","DOI":"10.1002\/pbc.26555"},{"key":"82273","doi-asserted-by":"crossref","unstructured":"Asselin B, Rizzari C. Asparaginase pharmacokinetics and implications of therapeutic drug monitoring. Leuk Lymphoma. 2015; 56(8):2273-2280.","DOI":"10.3109\/10428194.2014.1003056"},{"key":"82274","doi-asserted-by":"crossref","unstructured":"Salzer W, Bostrom B, Messinger Y, Perissinotti AJ, Marini B. Asparaginase activity levels and monitoring in patients with acute lymphoblastic leukemia. Leuk Lymphoma. 2018; 59(8):1797-1806.","DOI":"10.1080\/10428194.2017.1386305"},{"key":"82275","doi-asserted-by":"crossref","unstructured":"Daley RJ, Rajeeve S, Kabel CC. Tolerability and toxicity of pegaspargase in adults 40 years and older with acute lymphoblastic leukemia. Leuk Lymphoma. 2021; 62(1):176-184.","DOI":"10.1080\/10428194.2020.1824068"},{"key":"82276","unstructured":"Servier Pharmaceuticals LLC.. ASPARLAS\u2192 (calaspargase pegol-mknl). Prescribing Information. 2023."},{"key":"82277","unstructured":"Porton Biopharma Limited. Erwinase\u2192 (crisantaspase). Prescribing Information. 2016."},{"key":"82278","unstructured":"Jazz Pharmaceuticals. RYLAZE\u2192 [asparaginase erwinia chrysanthemi (recombinant)rywn] Prescribing Information. 2024."}],"container-title":["Haematologica"],"original-title":[],"link":[{"URL":"https:\/\/haematologica.org\/article\/download\/11989\/78193","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/11989\/79117","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/11989\/78193","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:08:25Z","timestamp":1794046105000},"score":1,"resource":{"primary":{"URL":"https:\/\/haematologica.org\/article\/view\/11989"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,20]]},"references-count":104,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2025,12,1]]}},"URL":"https:\/\/doi.org\/10.3324\/haematol.2024.286744","relation":{},"ISSN":["1592-8721","0390-6078"],"issn-type":[{"value":"1592-8721","type":"electronic"},{"value":"0390-6078","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3,20]]}}}